InvestSMART

Bionomics Limited (ASX: BNO) - Announcements

DELISTED - Current share price for BNO : $0.010

ASX company news and announcements for Bionomics Limited (BNO) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Bionomics Limited (BNO) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Bionomics Limited (BNO), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Bionomics Limited (BNO)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Commitments Test Entity - Third Quarter Report 26 Apr 2007 8:32AM $0.325 $0.010 fallen by 96.92%
- Open Briefing - Update on BNC105 Milestones 23 Apr 2007 10:03AM $0.305 $0.010 fallen by 96.72%
- Completion of GMP Synthesis 23 Apr 2007 8:56AM $0.305 $0.010 fallen by 96.72%
- Bionomics Presents Cancer Data at AACR Conference 17 Apr 2007 8:30AM $0.285 $0.010 fallen by 96.49%
- Half Yearly Report/Half Yearly Accounts 26 Feb 2007 11:53AM $0.270 $0.010 fallen by 96.30%
- Key Step Forward in Development of BNC105 21 Feb 2007 8:54AM $0.305 $0.010 fallen by 96.72%
- Commitments Test Entity - Second Quarter Report 30 Jan 2007 12:00PM $0.305 $0.010 fallen by 96.72%
- Meets with FDA in US 17 Jan 2007 9:18AM $0.270 $0.010 fallen by 96.30%
- To Benefit from $37.69m Federal CRC Grant 2 Jan 2007 9:55AM $0.280 $0.010 fallen by 96.43%
- Open Briefing.Bionomics.MD Updates Outlook 16 Nov 2006 11:51AM $0.220 $0.010 fallen by 95.45%
- Delivers on milestones for drug discovery programs 9 Nov 2006 10:15AM $0.220 $0.010 fallen by 95.45%
- Commitments Test Entity - First Quarter Report 27 Oct 2006 1:25PM $0.195 $0.010 fallen by 94.87%
- BNO & SAFC Pharma sign contract to manufacture BNC105 25 Oct 2006 9:07AM $0.180 $0.010 fallen by 94.44%
- Raises $5million through private Placement 21 Sep 2006 10:02AM n/a $0.010 n/a
- Collaborators advances new MS treatment 14 Sep 2006 9:22AM $0.150 $0.010 fallen by 93.33%
- Preliminary Final Report 22 Aug 2006 10:32AM $0.150 $0.010 fallen by 93.33%
- Commitments Test Entity - Fourth Quarter Report 24 Jul 2006 1:55PM $0.175 $0.010 fallen by 94.29%
- Open Briefing - MD on Update and Progress 20 Jun 2006 10:00AM $0.165 $0.010 fallen by 93.94%
- Bionomics Licensee Labcorp Launces Genetic Test for Epilepsy 8 Jun 2006 8:47AM $0.195 $0.010 fallen by 94.87%
- Commitments Test Entity - Third Quarter Report 28 Apr 2006 10:21AM $0.215 $0.010 fallen by 95.35%
- Commitments Test Entity - Third Quarter Report 28 Apr 2006 8:56AM $0.210 $0.010 fallen by 95.24%
- Nominates Cancer Drug Candidate 21 Apr 2006 10:17AM $0.215 $0.010 fallen by 95.35%
- Cancer Gene Patents Granted 13 Apr 2006 9:23AM $0.225 $0.010 fallen by 95.56%
- Bionomics Granted Epilepsy Gene Patent 11 Apr 2006 9:38AM $0.205 $0.010 fallen by 95.12%
- Open Briefing Bionomics MD on Cancer Program 5 Apr 2006 1:00PM $0.200 $0.010 fallen by 95%

726 - 750 of 801 results

Page 30 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.